The tweet was deleted by the author.
But we saved everything 🙂.
Amgen shared new data on cardiometabolic care at the #ADASciSessions 2026, the company said in a tweet.
Amgen said the data reinforce the need for more integrated approaches to prevention, risk reduction, and long-term management across obesity, diabetes, and cardiovascular disease.
AMGN is currently trading at $349.75, which is well above the MA-20 ($334.81), MA-50 ($340.69), and MA-200 ($329.36), indicating a strong short-, medium-, and long-term bullish bias. The Ichimoku Kijun on D1 is at $338.46, which sits below the current price and thus acts as immediate support.
Momentum signals on D1 are mixed, with MACD showing a neutral signal and ADX remaining weak at 12.26, indicating a limited trend strength. Oscillators such as the Stoch RSI (100.00) and CCI (248.31) are in overbought territory, while RSI is moderately bullish at 61.46. BBP points to persistent buyer dominance, and the Awesome Oscillator also supports bullish momentum. In today’s session, AMGN rose 1.20%. Over the past week, AMGN is trading at $349.75, up from $336.88—a 3.82% gain, with the price positioned at the very top of the weekly range and weekly volatility standing at 10.58%. This reflects a strong rally toward resistance with little consolidation.
For the coming week, the expected trading range is $340 to $358, keeping within a realistic band around the current price and anchored between this year’s low of $267.83 and high of $391.29. Based on W1 signals—RSI, MA-50, and MACD all showing “Buy” or “Strong Buy,” and ADX remaining neutral—the probability of an upward move is high (more than 80%), making further declines less likely. The baseline scenario is a sideways corridor between near-term support and resistance as momentum consolidates. A bullish breakout above $356–$358 could trigger a push toward the yearly high. A bearish break below the $340–$338 area would expose stronger support near $329, although this outcome currently has a very low probability.
Previously it was reported that Amgen shares were experiencing mixed momentum within a consolidation phase, as technical indicators suggested limited upside and prevailing downside risk. In the current context, investors should monitor for emerging shifts in price momentum, with any break above recent resistance levels likely to signal the start of a new directional trend.